Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPAIR: Remimazolam vs Propofol for Postoperative Recovery in Cytoreductive Surgery
NCT07785557Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Randomised, triple-blind trial of remimazolam in peritoneal neoplasms (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Quality of Recovery-15 total score at 48 hours. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
peritoneal neoplasms
Beyond the preview
Go deeper on NCT07785557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785557.